Sarepta’s DMD Gene Therapy: Approval Delayed And Indication Narrowed, But Still On Track

delay sign
Accelerated approval is expected in boys age four to five at first, but could grow pending the results of the EMBARK trial. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies